Vardenafil (Levitra/Staxyn) Compounding Legal Status

FDA Approval History and Regulatory Timeline

Vardenafil received its first FDA approval on August 19, 2003, under NDA 021400, marketed as Levitra by Bayer HealthCare Pharmaceuticals in partnership with GlaxoSmithKline [1]. The approval followed Phase III trials enrolling over 4,400 men with erectile dysfunction across multiple countries.

The Key Trials

The key efficacy data came from Porst et al. (2003), a randomized, double-blind, placebo-controlled trial of 580 men with ED. Vardenafil 5 mg, 10 mg, and 20 mg all produced statistically significant improvements in the International Index of Erectile Function (IIEF) erectile function domain score compared to placebo (P<0.001 for all doses). The 20 mg dose improved successful intercourse attempts from 32% at baseline to 75% [1]. This trial formed one of the core data packages the FDA reviewed.

Staxyn and Formulation Expansion

A second formulation, Staxyn (vardenafil orally disintegrating tablet, 10 mg), gained FDA approval on June 17, 2010, under NDA 022488 [2]. Staxyn uses a different salt form (vardenafil monohydrochloride trihydrate is used in Levitra; Staxyn uses the free-base in an ODT matrix) and is not interchangeable with Levitra on a milligram-per-milligram basis. The FDA label explicitly states: "Do not substitute Staxyn for Levitra" [2].

Generic Entry

Bayer's core compound patent (US Patent 6,362,178) and its pediatric exclusivity extension expired in 2018. The first generic vardenafil hydrochloride tablets (via ANDA filings) became available in October 2018 from manufacturers including Par Pharmaceutical and Aurobindo. Multiple generics are now on the market in 2.5 mg, 5 mg, 10 mg, and 20 mg strengths [3].

Current Compounding Legal Framework

Compounding vardenafil falls under two distinct regulatory pathways in the United States: section 503A for traditional compounding pharmacies and section 503B for outsourcing facilities. The rules differ substantially between these pathways, and the commercial availability of generic vardenafil adds a significant constraint.

Section 503A: Traditional Compounding Pharmacies

Under section 503A of the FD&C Act, a licensed pharmacist may compound vardenafil for an individual patient if a valid prescription exists and the compounded preparation is not "essentially a copy" of a commercially available drug product [4]. This is the critical restriction. A 503A pharmacy cannot compound a vardenafil 20 mg tablet that is therapeutically identical to commercially available generic vardenafil 20 mg tablets.

What a 503A pharmacy can do: prepare a vardenafil formulation in a dosage form or strength not commercially available (for example, a vardenafil sublingual troche in a non-standard strength like 8 mg), provided a prescriber has determined a medical need for that specific preparation for a specific patient.

Section 503B: Outsourcing Facilities

Section 503B outsourcing facilities, registered with the FDA and subject to current Good Manufacturing Practice (cGMP) requirements, may compound without individual prescriptions and distribute to healthcare facilities [5]. These facilities appear on the FDA's publicly searchable outsourcing facility registry.

503B facilities face the same "essentially a copy" limitation. They cannot produce vardenafil products that duplicate commercially available formulations unless the drug appears on the FDA Drug Shortage List. As of May 2026, vardenafil is not listed as a shortage drug [6].

The "Essentially a Copy" Doctrine

The FDA's guidance on "essentially a copy" defines the term as a drug that is identical or nearly identical to a commercially available product in active ingredient, route, dosage form, and strength. A compounded vardenafil 10 mg sublingual troche would generally not be considered an essentially-a-copy of Levitra 10 mg film-coated tablets because the dosage form and route differ. A compounded vardenafil 20 mg oral tablet would likely be considered a copy [4].

Vardenafil FDA Label: Key Safety and Prescribing Details

The current vardenafil prescribing information contains several boxed and bolded warnings that apply equally to branded, generic, and any legally compounded formulations.

Cardiovascular Warnings

The label carries a prominent warning against co-administration with nitrates in any form. The FDA label states: "Administration of PDE5 inhibitors, including vardenafil, with nitric oxide donors such as organic nitrates or organic nitrites in any form is contraindicated" [2]. This includes nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, and recreational amyl nitrite. The combination can produce severe, potentially fatal hypotension.

QT Prolongation

Vardenafil is unique among PDE5 inhibitors in carrying a specific QT prolongation warning. A thorough QT study showed that vardenafil 10 mg prolonged the QTc interval by a mean of 8 ms, with the maximum individual QTc increase reaching 15 ms [2]. The label advises against use in patients with congenital QT prolongation, those taking Class IA or Class III antiarrhythmics, and those with a QTc >500 ms.

Hepatic and Renal Dosing Adjustments

For patients with moderate hepatic impairment (Child-Pugh B), the recommended starting dose is 5 mg, with a maximum of 10 mg. Vardenafil is not recommended for patients with severe hepatic impairment (Child-Pugh C). No dose adjustment is required for mild-to-moderate renal impairment [2].

Why Compounded Vardenafil Exists Despite Generic Availability

The commercial availability of generic vardenafil has not eliminated demand for compounded formulations. Several legitimate clinical scenarios drive prescribers toward compounding pharmacies.

Non-Standard Dosage Forms

Some patients cannot swallow tablets or require faster onset than oral tablets provide. Compounding pharmacies prepare vardenafil as sublingual troches, topical creams, or oral suspensions. These dosage forms are not commercially manufactured. A sublingual troche, for example, bypasses hepatic first-pass metabolism and may produce faster onset, though no FDA-approved data quantify this difference for vardenafil specifically.

Combination Products

Compounding pharmacies frequently combine vardenafil with other active ingredients in a single preparation. Common combinations include vardenafil with oxytocin (for patients who may benefit from both vasodilation and the neurohormonal effects of oxytocin) or vardenafil combined with apomorphine. No commercially manufactured combination product containing vardenafil exists. These combinations require a prescriber's individualized assessment and a valid prescription.

Dose Customization

While Levitra is available in 2.5 mg, 5 mg, 10 mg, and 20 mg strengths, some prescribers prefer intermediate doses (such as 7.5 mg or 15 mg) or micro-doses below 2.5 mg. Compounding can accommodate these non-standard strengths. Splitting a 5 mg tablet does not reliably produce two equal 2.5 mg halves due to the film coating and tablet geometry.

Safety Risks of Compounded Vardenafil

Compounded drugs are not FDA-approved products. They do not undergo the same premarket review for safety, efficacy, and quality that commercially manufactured drugs receive.

Potency Variability

The FDA has documented potency failures in inspections of compounding pharmacies. Between 2020 and 2024, approximately 28% of tested compounded products failed potency specifications during FDA inspections of 503B outsourcing facilities [7]. For a drug like vardenafil, where the therapeutic window ranges from 5 to 20 mg and where cardiovascular effects are dose-dependent, potency deviations carry real clinical risk.

Contamination and Sterility

For compounded injectable formulations (used in intracavernosal injections containing vardenafil as part of combination products), sterility is critical. The FDA's adverse event reporting system (FAERS) has logged reports of infection associated with contaminated compounded ED products, though these are not disaggregated by specific active ingredient [7].

Regulatory Enforcement Actions

The FDA has issued warning letters and injunctions against compounding pharmacies that produced copies of commercially available PDE5 inhibitors. In 2019, the FDA took action against several pharmacies marketing compounded erectile dysfunction products online without valid prescriptions [8]. Patients should verify that any compounding pharmacy they use holds a valid state license and, if it is an outsourcing facility, appears on the FDA's 503B registry.

How to Verify a Compounding Pharmacy's Legitimacy

Patients receiving compounded vardenafil should take three verification steps before filling a prescription.

Check State Licensure

Every state board of pharmacy maintains a public database of licensed pharmacies. The National Association of Boards of Pharmacy (NABP) offers a Verified Pharmacy Program database. An unlicensed operation selling "compounded vardenafil" online without requiring a prescription is operating illegally.

Confirm 503B Registration (If Applicable)

If the pharmacy claims to be an outsourcing facility, its name should appear on the FDA's list of registered outsourcing facilities. This list is updated regularly and includes inspection history [5].

Ask About Testing

Reputable compounding pharmacies, especially 503B outsourcing facilities, perform potency and sterility testing on finished preparations. Patients and prescribers can request certificates of analysis (COAs). A pharmacy unwilling to provide a COA should raise concern.

State-Level Variation in Compounding Regulations

Federal law sets the baseline, but individual states add their own compounding regulations. These variations affect what compounded vardenafil products patients can access depending on where they live.

Stricter States

States like California, New York, and Massachusetts impose additional compounding requirements beyond federal 503A/503B standards. California's Board of Pharmacy, for example, requires compounding pharmacies to submit annual self-assessment forms and subjects them to more frequent inspections. New York requires compounding pharmacies to register separately with the state health department [9].

Interstate Shipping Limitations

A 503A pharmacy generally cannot ship compounded products across state lines (with narrow exceptions). 503B outsourcing facilities, however, can distribute nationally. This distinction matters for telehealth prescriptions: a patient in Texas receiving a telehealth prescription from a provider in Florida can have it filled by a 503B outsourcing facility but typically not by a 503A pharmacy in a different state [4][5].

International Regulatory Comparison

Vardenafil's regulatory status outside the United States provides useful context for patients who travel or consider purchasing from international sources.

The European Medicines Agency (EMA) approved Levitra in March 2003 under EU/1/03/248, roughly five months before the FDA approval [10]. The EMA's Committee for Medicinal Products for Human Use (CHMP) conducted its own review of the same Phase III dataset. Compounding (called "magistral preparation" in EU terminology) is governed by individual EU member states. Most EU countries restrict magistral preparation of products with commercially available equivalents, similar to the U.S. "essentially a copy" restriction.

In the United Kingdom (post-Brexit), vardenafil remains prescription-only. The MHRA has not approved any compounded vardenafil for sale. In Australia, the Therapeutic Goods Administration (TGA) classifies vardenafil as Schedule 4 (prescription only), and compounding is regulated under state pharmacy legislation [10].

Purchasing vardenafil from unregulated international online pharmacies carries substantial risk. The FDA's BeSafeRx campaign has identified counterfeit PDE5 inhibitor products containing incorrect active ingredients, incorrect doses, or toxic contaminants.

The Telehealth Factor

The expansion of telehealth prescribing since 2020 has increased demand for compounded ED medications, including vardenafil formulations. Several direct-to-consumer telehealth platforms prescribe compounded combinations that include vardenafil.

Patients should confirm that any telehealth-prescribed compounded vardenafil meets three criteria: the prescriber holds an active medical license in the patient's state, a legitimate patient-provider relationship exists (including medical history review and, where clinically indicated, lab work), and the compounding pharmacy is properly licensed and registered. The DEA's expanded telehealth prescribing flexibilities (extended through 2025 and subsequently codified in part) apply to controlled substances and do not directly affect vardenafil, which is unscheduled [8].

Prescribers ordering compounded vardenafil through telehealth platforms should document the clinical rationale for a compounded formulation rather than a commercially available generic, particularly when the compounded product uses the same route and a similar strength.